Status | Study |
Completed |
Study Name: Imatinib in KIT-negative Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2011-02-16 Interventions: Drug: Imatinib Mesylate In |
Completed |
Study Name: Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation Condition: Patients With Mastocytosis With Handicap and Bearing Mutations Asp-816-Val (D816V) Date: 2010-12-23 Interventions: Drug: masitinib |
Completed |
Study Name: Evaluation of Response of Dasatinib to Treat Mastocytosis Condition: Systemic Mastocytosis Date: 2009-09-16 Interventions: Drug: Dasatinib Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient w |
Completed |
Study Name: The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Condition: Mastocytosis Date: 2009-07-20 Interventions: Drug: injections subcutaneous injections |
Terminated |
Study Name: Obatoclax for Systemic Mastocytosis Condition: Leukemia Systemic Mastocytosis Date: 2009-06-09 Interventions: Drug: Obatoclax Mesylate 30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle. |
Completed |
Study Name: Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis Condition: Mastocytosis Date: 2009-01-28 Interventions: Drug: masitinib (AB1010) 3 mg/ |
Completed |
Study Name: Use of Tamoxifen in Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2007-12-25 |
Completed |
Study Name: Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Condition: Leukemia Systemic Mastocytosis Date: 2007-06-26 Interventions: Drug: Ontak (Denileukin Diftitox) 9 µg/kg by vein Days 1-5 of a 21 day cycle. |
Completed |
Study Name: Efficacy and Safety of TF002 in Cutaneous Mastocytosis Condition: Cutaneous Mastocytosis Date: 2007-04-04 Interventions: Drug: TF 002 |
Completed |
Study Name: Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Condition: Systemic Mastocytosis Date: 2007-03-19 Interventions: Drug: RAD001 (Everolimus) Oral RAD001 10 mg daily for 30 days |